High Tumor Volume to Fetal Weight Ratio Is Associated with Worse Fetal Outcomes and Increased Maternal Risk in Fetuses with Sacrococcygeal Teratoma.


Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2019
Historique:
received: 25 10 2017
accepted: 29 12 2017
pubmed: 2 3 2018
medline: 12 9 2019
entrez: 2 3 2018
Statut: ppublish

Résumé

Tumor volume to fetal weight ratio (TFR) > 0.12 before 24 weeks has been associated with poor outcome in fetuses with sacrococcygeal teratoma (SCT). We evaluated TFR in predicting poor fetal outcome and increased maternal operative risk in our cohort of SCT pregnancies. This is a retrospective, single-center review of fetuses seen with SCT from 1997 to 2015. Patients who chose termination of pregnancy (TOP), delivered elsewhere, or had initial evaluation at > 24 weeks were excluded. Receiver operating characteristic (ROC) analysis determined the optimal TFR to predict poor fetal outcome and increased maternal operative risk. Poor fetal outcome included fetal demise, neonatal demise, or fetal deterioration warranting open fetal surgery or delivery < 32 weeks. Increased maternal operative risk included cases necessitating open fetal surgery, classical cesarean delivery, or ex utero intrapartum treatment (EXIT). Of 139 pregnancies with SCT, 27 chose TOP, 14 delivered elsewhere, and 40 had initial evaluation at > 24 weeks. Thus, 58 fetuses were reviewed. ROC analysis revealed that at ≤24 weeks, TFR > 0.095 was predictive of poor fetal outcome and TFR > 0.12 was predictive of increased maternal operative risk. This study supports the use of TFR at ≤24 weeks for risk stratification of pregnancies with SCT.

Identifiants

pubmed: 29495013
pii: 000486782
doi: 10.1159/000486782
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-101

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Juliana S Gebb (JS)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USAjulianagebb@gmail.com.

Nahla Khalek (N)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Huma Qamar (H)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Mark P Johnson (MP)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Edward R Oliver (ER)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Beverly G Coleman (BG)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

William H Peranteau (WH)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Holly L Hedrick (HL)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Alan W Flake (AW)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

N Scott Adzick (NS)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Julie S Moldenhauer (JS)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH